{"id":"optive-plus","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"Sodium hyaluronate is a natural component of the eye that helps retain moisture, while polyethylene glycol acts as a surfactant to spread the solution evenly over the cornea, reducing dryness and irritation.","oneSentence":"OPTIVE PLUS® contains sodium hyaluronate and polyethylene glycol, which work together to lubricate and protect the ocular surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:41:32.217Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye syndrome"}]},"trialDetails":[{"nctId":"NCT07284381","phase":"PHASE3","title":"A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-12-15","conditions":"Dry Eye Disease","enrollment":250},{"nctId":"NCT06221345","phase":"PHASE4","title":"Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-12-07","conditions":"Dry Eye Disease, Cataract","enrollment":70},{"nctId":"NCT02776670","phase":"NA","title":"Clinical Outcomes Following Treatment With SYSTANE® BALANCE","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-07-29","conditions":"Dry Eye","enrollment":308},{"nctId":"NCT02117687","phase":"PHASE4","title":"A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05-14","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":80},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT02280473","phase":"PHASE3","title":"A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-11-13","conditions":"Dry Eye Syndromes","enrollment":188},{"nctId":"NCT01459588","phase":"PHASE3","title":"Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10-01","conditions":"Dry Eye Syndromes","enrollment":315},{"nctId":"NCT02553772","phase":"PHASE3","title":"A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-01-06","conditions":"Dry Eye Syndromes","enrollment":242},{"nctId":"NCT03140111","phase":"NA","title":"LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients","status":"UNKNOWN","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2017-10-16","conditions":"Dry Eye Syndromes, Primary Sjögren Syndrome","enrollment":12},{"nctId":"NCT03052140","phase":"NA","title":"Lamelleye vs Comparator for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Glasgow Caledonian University","startDate":"2017-02-21","conditions":"Dry Eye Syndromes","enrollment":31},{"nctId":"NCT00691197","phase":"PHASE2, PHASE3","title":"Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-03","conditions":"Ametropia","enrollment":246},{"nctId":"NCT01799863","phase":"PHASE2, PHASE3","title":"Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis","status":"COMPLETED","sponsor":"Fundação Altino Ventura","startDate":"2012-06","conditions":"Conjunctivitis, Viral","enrollment":50},{"nctId":"NCT01711424","phase":"","title":"An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-09","conditions":"Dry Eye Syndromes","enrollment":1209},{"nctId":"NCT00761202","phase":"PHASE4","title":"Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-08","conditions":"Dry Eye Syndromes","enrollment":50},{"nctId":"NCT00405457","phase":"PHASE4","title":"Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"2006-11","conditions":"Dry Eye","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"OPTIVE PLUS®","genericName":"OPTIVE PLUS®","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPTIVE PLUS® contains sodium hyaluronate and polyethylene glycol, which work together to lubricate and protect the ocular surface. Used for Dry eye syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}